Search research articles
Contact Us
Filters
Showing results (51-60 of 77) with videos related to
Page
of 8
Sort By:
Blood
|
July 31, 2020
A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma
Nancy L Bartlett, Alex F Herrera, Eva Domingo-Domenech, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 19, 2019
Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies
Gerald Falchook, Seth Rosen, Patricia LoRusso, et al.
Lancet (London, England)
|
September 5, 2020
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
Jeremy S Abramson, M Lia Palomba, Leo I Gordon, et al.
Blood Advances
|
March 26, 2024
Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma
Pier Luigi Zinzani, Gilles Salles, Alison J Moskowitz, et al.
Journal of the American Academy of Dermatology
|
October 1, 2025
Racial differences in mycosis fungoides and Sézary syndrome: A multicenter cohort study
Pamela B Allen, Subir Goyal, Swaminathan Iyer, et al.
Blood
|
May 5, 2017
PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD
Bradley M Haverkos, Diana Abbott, Mehdi Hamadani, et al.
Nature Medicine
|
December 10, 2023
Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial
Lihua E Budde, Adam J Olszewski, Sarit Assouline, et al.
BJU International
|
November 14, 2013
A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma
Gregory R Pond, Neeraj Agarwal, Joaquim Bellmunt, et al.
Plos Medicine
|
June 29, 2023
Exposure of progressive immune dysfunction by SARS-CoV-2 mRNA vaccination in patients with chronic lymphocytic leukemia: A prospective cohort study
Kai Qin, Kazuhito Honjo, Scott Sherrill-Mix, et al.
Medrxiv : the Preprint Server for Health Sciences
|
January 4, 2023
SARS-CoV-2 mRNA vaccination exposes progressive adaptive immune dysfunction in patients with chronic lymphocytic leukemia
Kai Qin, Kazuhito Honjo, Scott Sherrill-Mix, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 77) with videos related to
Sort By:
Page
of 8
Blood
|
July 31, 2020
A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma
Nancy L Bartlett, Alex F Herrera, Eva Domingo-Domenech, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 19, 2019
Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies
Gerald Falchook, Seth Rosen, Patricia LoRusso, et al.
Lancet (London, England)
|
September 5, 2020
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
Jeremy S Abramson, M Lia Palomba, Leo I Gordon, et al.
Blood Advances
|
March 26, 2024
Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma
Pier Luigi Zinzani, Gilles Salles, Alison J Moskowitz, et al.
Journal of the American Academy of Dermatology
|
October 1, 2025
Racial differences in mycosis fungoides and Sézary syndrome: A multicenter cohort study
Pamela B Allen, Subir Goyal, Swaminathan Iyer, et al.
Blood
|
May 5, 2017
PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD
Bradley M Haverkos, Diana Abbott, Mehdi Hamadani, et al.
Nature Medicine
|
December 10, 2023
Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial
Lihua E Budde, Adam J Olszewski, Sarit Assouline, et al.
BJU International
|
November 14, 2013
A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma
Gregory R Pond, Neeraj Agarwal, Joaquim Bellmunt, et al.
Plos Medicine
|
June 29, 2023
Exposure of progressive immune dysfunction by SARS-CoV-2 mRNA vaccination in patients with chronic lymphocytic leukemia: A prospective cohort study
Kai Qin, Kazuhito Honjo, Scott Sherrill-Mix, et al.
Medrxiv : the Preprint Server for Health Sciences
|
January 4, 2023
SARS-CoV-2 mRNA vaccination exposes progressive adaptive immune dysfunction in patients with chronic lymphocytic leukemia
Kai Qin, Kazuhito Honjo, Scott Sherrill-Mix, et al.
Page
of 8